# Enterin

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enterin

- Industry: Pharmaceuticals
- Headquarters: Philadelphia, US
- Website: www.enterininc.com
- Total disclosed funding: $13M
- Latest round: Series A (Jul 10, 2017)
- Investors on record: 1

## About

Enterin Inc. is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, particularly Parkinson's disease, by enhancing drug delivery to the central nervous system.Founded in 2016 and headquartered in Philadelphia, US, Enterin Inc. specializes in therapeutics for neurodegenerative diseases. The company, co-founded by Denise Frcp and Michael Zasloff, has participated in 3 deals with its most recent funding round occurring on October 4, 2022, where it raised USD 6.00 mn in Venture Debt from Voloridge and other investors. The total funds raised by Enterin now stand at USD 16.70 mn.Enterin Inc. specializes in the development of innovative therapeutics aimed at addressing neurodegenerative diseases, with a particular focus on Parkinson's disease. Their flagship product is a novel drug candidate designed to enhance the delivery of therapies to the central nervous system, thereby improving the efficacy of treatment outcomes for patients. Enterin's approach targets the underlying mechanisms of neurodegeneration, aiming to alleviate symptoms and potentially slow disease progression. The company’s products are currently in various stages of clinical development, with a target market that includes healthcare providers, research institutions, and pharmaceutical companies across North America and Europe. By focusing on a niche segment within the biotechnology landscape, Enterin seeks to serve a patient population that has limited treatment options available, ultimately enhancing the quality of life for individuals affected by these debilitating conditions.Enterin Inc. generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical entities, which may involve co-development agreements and licensing deals for their proprietary drug candidates. Transactions typically revolve around milestone payments tied to the achievement of specific clinical development phases, as well as potential royalties on future sales of marketed products. The company’s revenue model may include contractual agreements that stipulate shared responsibilities in research and development, reflecting a B2B transaction structure that emphasizes collaboration. As the company advances its clinical programs, it is positioned to benefit from various funding mechanisms, including grants and investor financing, which support the continued progress of their research initiatives. This structured approach not only facilitates necessary capital inflow but also enhances the potential for successful product commercialization in the future.Following the recent funding of USD 6.00 mn raised on October 4, 2022, Enterin Inc. plans to leverage these funds to support the further development of its innovative therapeutics. The company is looking to expand its product offerings with new drugs targeting Parkinson's disease, although specific release dates have not been disclosed. Additionally, Enterin aims to expand its market reach into Europe and Asia by 2025, seeking strategic partnerships that will facilitate entry into these regions.

## Funding rounds

- Series A, Jul 10, 2017, $13M — Scientia Ventures

## Investors

- Scientia Ventures (https://capitalatlas.ai/funds/scientia-ventures) — Series A